secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001099800-25-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q4 sales $1.39B (+9%), adjusted EPS $0.59; reiterates 2025 guidance
---------------------------------------------------------------------------

- Q4 sales $1.39B (+9% YoY); TAVR $1.04B (+6%), TMTT $105M (+88%).
- GAAP EPS $0.58; adjusted EPS $0.59; full-year sales from continuing ops $5.5B.
- 2025 guidance reaffirmed: constant currency sales growth 8-10%, adjusted EPS $2.40-$2.50.
- Expect mid-year FDA approval for asymptomatic TAVR; presented EARLY TAVR and TRISCEND II trials.
- Cash $3.0B; debt $600M; adjusted gross margin 79.0%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980025000003/0001099800-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980025000003/ew-20250211.htm
  HTML page:      https://secwatch.observer/filing/0001099800-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer